Login to Your Account



Serono In-Licenses Newron's Parkinson's Drug For $200M

By Cormac Sheridan


Wednesday, October 18, 2006
Completing one last deal before finalizing its merger with Merck KGaA, Serono SA gained exclusive rights from Newron Pharmaceuticals SpA to safinamide, a compound undergoing a Phase III trial in Parkinson's disease, for up to $200 million. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription